P1, N=60, Recruiting, Daiichi Sankyo | N=13 --> 60

P1, N=100, Active, not recruiting, Daiichi Sankyo Co., Ltd. | Trial completion date: Dec 2026 --> Dec 2027

Pharmacological inhibition of EZH2 using DS-3201 reproduced some of the molecular effects of viral infection, including increased mutp53 stability...Indeed, the inhibition of SIRT1 with EX-527 reversed mutp53 accumulation but restored c-Myc expression and increased extracellular IL-6 release...These results establish a mechanistic link between viral infection, epigenetic remodeling, and oncogenic dependency. They also suggest that targeting IL-6 signaling could represent a therapeutic vulnerability in HHV-6A-associated thyroid cancer, particularly in combination with SIRT1 inhibitors.

P2, N=900, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris

P1/2, N=165, Recruiting, Dizal Pharmaceuticals | Not yet recruiting --> Recruiting

P1/2, N=188, Recruiting, Novartis Pharmaceuticals

P1/2, N=165, Not yet recruiting, Dizal Pharmaceuticals

An 80-year-old woman with relapsed nodal T-follicular helper cell lymphoma, not otherwise specified, developed severe watery diarrhea during valemetostat therapy...To the best of our knowledge, this is the first reported case of enhancer of zeste homolog 1 and 2 (EZH1/2) inhibitor-induced colitis. EZH1/2 inhibition may lead to T cell-mediated intestinal injury through epigenetic dysregulation; therefore, patients receiving EZH1/2 inhibitors who develop persistent diarrhea should undergo early endoscopic and histological evaluations.

P1, N=4, Not yet recruiting, Daiichi Sankyo Inc.

At the last follow-up, four patients were alive without disease, four were alive with disease, and three died due to progressive disease. Hence, valemetostat is a promising salvage therapy for relapsed adult T-cell leukemia/lymphoma after allo-HCT.

P2, N=900, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting

P1/2, N=76, Recruiting, Novartis Pharma AG | Not yet recruiting --> Recruiting